期刊文献+

1%聚桂醇在面部血管瘤及血管畸形治疗中的应用 被引量:29

Application of 1% lauromacrogol in the treatment of facial refractory hemangioma and vascular malformations
原文传递
导出
摘要 目的探讨1%聚桂醇注射液治疗面部血管瘤及血管畸形的临床疗效。方法2009年9月至2011年11月,临床治疗55例不同类型的颜面部难治性血管瘤及血管畸形患者,男20例,女35例,年龄为1个月至30岁,瘤体面积为1.0am×(0.5—5.0)cm×10.0cm,采用1%聚桂醇瘤内注射治疗,根据患者的年龄、瘤体大小和深度决定用药浓度、剂量和注射次数,个体1次最大剂量不超过10ml,两次注射间隔为1—4周。结果经3—16个月随访,治愈41例,基本治愈9例,有效5例。2例出现局部皮肤破溃,换药后创面愈合。结论1%聚桂醇作为一种硬化剂治疗颜面部难治性血管性疾病,安全有效,且简单易行。 Objective To investigate the clinical effect of 1% lauromacrogol for the treatment of facial refractory hemangioma and vascular malformation. Methods From Sept 2009 to Nov 2011, 55 patients (20 male, 35 female, 1 month to 30 years) with different types of facial hemangioma and vascular malformation about 1.0 cm ·(0. 5-5.0) cm · 10.0 cm in size, underwent 1% lauromacrogol intratumor injection therapy. Generally, the injection dose, concentration, frequency were determined by the age of the patients, the volume and depth of the lesion. The dose was limited to 10 mg every time. The injection interval is 1--4 weeks. Results After followed up for 3-16 months, 41 cases were cured, 9 cases were greatly improved, and 5 were partially improved. Skin necrosis happened in only 2 cases. Conclusions Lauromacrogol is safe, simple and effective as a sderosing agent for the treatment of facial refractory hemangioma and vascular malformation. It provides a new and alternative way for the treatment of facial refractory hemangioma and vascular malformation.
出处 《中华整形外科杂志》 CAS CSCD 北大核心 2012年第6期428-431,共4页 Chinese Journal of Plastic Surgery
关键词 聚桂醇 血管瘤 血管畸形 Lauromacrogol Hemangioma Vascular malformation
  • 相关文献

参考文献11

二级参考文献119

  • 1陈达,林晓曦,李伟.血管瘤中缺氧诱导因子-1α的表达和血管生成的研究[J].中华整形外科杂志,2005,21(2):115-118. 被引量:13
  • 2倪蓉,倪娟.放射性核素^(90)锶治疗血管瘤的临床效果[J].临床医学,2005,25(10):52-53. 被引量:4
  • 3郑家伟,秦中平,张志愿,周国瑜.口服皮质激素治疗婴幼儿口腔颌面部血管瘤[J].中国口腔颌面外科杂志,2006,4(3):228-232. 被引量:52
  • 4赵永强.易栓症研究概况[J].中国实用内科杂志,2007,27(1):49-52. 被引量:58
  • 5AI Samaraee A, McCallum IJ, Mudawi A. Endovenous therapy of varicose veins: a better outcome than standard surgery? [J]. Surgeon, 2009, 7(3): 181-186.
  • 6Zimmet SE. Sclerotherapy treatment of telangiectasias and varicose veins [ J ]. Tech Vasc Interv Radiol, 2003, 6 (3) : 116-120.
  • 7Rabe E, Otto J, Schliephak D, et al. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF) : a randomised controlled multicentre clinical trial [ J ]. Eur J Vasc Endovasc Surg, 2008, 35(2): 238-245.
  • 8Ouvry P, Allaert FA, Desnos P, et al. Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a muhicentre randomised controlled trial with a 2-year follow-up [ J ]. Eur J Vasc Endovasc Surg, 2008, 36(3) : 366-370.
  • 9Levy JL, Trelles MA, Levy A, et al. Photography in dermatology: comparison between slides and digital imaging[J]. J Cosmet Dermatol, 2003, 2 (3-4) : 131- 134.
  • 10Blaise S, Bosson JL, Diamand JM. Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up [ J ]. Eur J Vasc Endovasc Surg, 2010, 39(6) : 779-786.

共引文献181

同被引文献282

引证文献29

二级引证文献145

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部